Literature DB >> 29664384

Seroprevalence of Severe Fever with Thrombocytopenia Syndrome Virus Antibodies in Rural Areas, South Korea.

Mi Ah Han, Choon-Mee Kim, Dong-Min Kim, Na Ra Yun, Sun-Whan Park, Myung Guk Han, Won-Ja Lee.   

Abstract

We investigated 1,228 residents of 3 rural areas in South Korea and determined that 50 (4.1%) were positive for severe fever with thrombocytopenia syndrome virus antibodies. Fever and gastrointestinal symptoms in the previous 3 years and career duration were associated with virus seropositivity.

Entities:  

Keywords:  SFTS; SFTSV; South Korea; antibodies; rural areas; seroprevalence; severe fever with thrombocytopenia syndrome; severe fever with thrombocytopenia syndrome virus; ticks; vector-borne infections; viruses

Mesh:

Year:  2018        PMID: 29664384      PMCID: PMC5938763          DOI: 10.3201/eid2405.152104

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Severe fever with thrombocytopenia syndrome (SFTS) is a tick-transmitted, acute febrile disease caused by SFTS virus (SFTSV) (,). Previous studies have not determined the seroprevalence of SFTSV in South Korea. Therefore, we investigated SFTSV seroprevalence among residents of rural areas in South Korea and identified factors associated with seropositivity.

The Study

We conducted our study in rural areas of 3 provinces (Myeoncheon-myeon, Dangjin-gun, Choongcheongnam-do Province; Nodong-myeon, Boseong-gun, Jeollanam-do Province; and Gahoe-myeon, Hapcheon-gun, Gyeosangnam-do Province) in South Korea that had reported SFTS patients to the Korean Center for Disease Control during 2013–2014 (Figure 1) (). In September 2014, we administered a structured questionnaire regarding demographic characteristics and occupational and living conditions to 1,228 residents of these areas. We collected blood samples from these persons and subjected them to indirect immunofluorescent assays to determine SFTSV IgG titers. Participants were defined as being seropositive if the indirect immunofluorescent assay IgG titer was >1:32 (Figure 2). Written consent was obtained from all participants before administration of the survey and blood tests. This study was approved by the Chosun University Institutional Review Board.
Figure 1

Seroprevalence in 3 rural areas (2014) and incidence in 8 provinces (2013–2014) of severe fever with thrombocytopenia syndrome, South Korea. Within each province, 1 rural area was selected on the basis of the number of cases. Green circles indicate seroprevalence determined by using an indirect immunofluorescence assay. The incidence rate is per 1 million persons.

Figure 2

Representative indirect immunofluorescent assays of Vero E6 cells infected with thrombocytopenia syndrome virus from patients in rural areas, South Korea. Indirect immunofluorescent assays were conducted by using serially diluted patient serum as primary antibody and fluorescein isothiocyanate–conjugated antihuman IgG as secondary antibody. A) H1 serum (negative, dilution 1:32, IgG titer <1:32); B) B321 serum (positive, dilution 1:64, IgG titer 1:512); C) H214 serum (positive, dilution 1:32, IgG titer 1:128); D) D127 serum (positive, dilution 1:32, IgG titer 1:256). Original magnification x400.

Seroprevalence in 3 rural areas (2014) and incidence in 8 provinces (2013–2014) of severe fever with thrombocytopenia syndrome, South Korea. Within each province, 1 rural area was selected on the basis of the number of cases. Green circles indicate seroprevalence determined by using an indirect immunofluorescence assay. The incidence rate is per 1 million persons. Representative indirect immunofluorescent assays of Vero E6 cells infected with thrombocytopenia syndrome virus from patients in rural areas, South Korea. Indirect immunofluorescent assays were conducted by using serially diluted patient serum as primary antibody and fluorescein isothiocyanate–conjugated antihuman IgG as secondary antibody. A) H1 serum (negative, dilution 1:32, IgG titer <1:32); B) B321 serum (positive, dilution 1:64, IgG titer 1:512); C) H214 serum (positive, dilution 1:32, IgG titer 1:128); D) D127 serum (positive, dilution 1:32, IgG titer 1:256). Original magnification x400. Of 1,228 persons included in the analysis (Table 1), 786 (64.0%) were women, 831 (67.7%) were >65 years of age, and 713 (58.1%) worked in agriculture. A total of 225 (18.3%) participants had lived in the same residence for 1–20 years, and 757 (61.6%) had lived in the same residence for >41 years; 255 (20.8%) had raised domestic animals and livestock (among which dogs were most common). Furthermore, 166 (13.5%) had received a tick bite during their lifetime (Table 1). The highest tick bite rate was reported in Boseong (94, 26.8%), followed by Hapcheon (43, 10.7%) and Dangjin (29, 7.1%). In the year before the study, 75 (6.1%) of patients in the total cohort had a tick bite (Boseong: 52, 12.5%; Dangjin: 13, 3.2%; Hapcheon: 10, 2.5%), and 25 (2.0%) had a fever and gastrointestinal (GI) symptoms (i.e., SFTS symptoms) during the previous 3 years.
Table 1

Epidemiologic characteristics for 1,228 patients with suspected SFTS in rural areas, South Korea*

Characteristic
Total, no. (%)
Seronegative, no. (%)
Seropositive, no. (%)
p value†
No. patients1,228 (100.0)1,178 (95.9)50 (4.1)
Area0.116
Bosung416 (33.9)393 (94.5)23 (5.5)
Dangjin411 (33.5)400 (97.3)11 (2.7)
Hapcheon401 (32.7)385 (96.0)16 (4.0)
Sex
M442 (36.0)425 (96.2)17 (3.9)0.764
F786 (64.0)753 (95.8)33 (4.2)
Age, y0.027
<64397 (32.3)388 (97.7)9 (2.3)
>65831 (67.7)790 (95.1)41 (4.9)
Education level0.489
Uneducated (illiterate)318 (25.9)303 (95.3)15 (4.7)
Uneducated (literate)165 (13.5)158 (95.8)7 (4.2)
Elementary school361 (29.5)343 (95.0)18 (5.0)
Middle school193 (15.7)187 (96.9)6 (3.1)
More than high school189 (15.4)185 (97.9)4 (2.1)
Smoking status0.324
Never876 (71.4)845 (96.5)31 (3.5)
Former205 (16.7)194 (94.6)11 (5.4)
Current146 (11.9)138 (94.5)8 (5.5)
Drinking frequency, no. drinks0.587
None712 (58.0)683 (95.9)29 (4.1)
<1/mo164 (13.4)159 (97.0)5 (3.1)
<3/wk100 (8.1)93 (93.0)7 (7.0)
4–6/wk148 (12.1)143 (96.6)5 (3.4)
Every day104 (8.5)100 (96.2)4 (3.9)
Chronic disease0.492
None318 (25.9)306 (96.2)12 (3.8)
1417 (34.0)403 (96.6)14 (3.4)
>2493 (40.2)469 (95.1)24 (4.9)
Residency duration, y0.023
1–20225 (18.3)221 (98.2)4 (1.8)
21–40246 (20.0)240 (97.6)6 (2.4)
>41757 (61.6)717 (94.7)40 (5.3)
No. family members0.074
0 (alone) or 1954 (77.7)910 (95.4)44 (4.6)
>2274 (22.3)268 (97.8)6 (2.2)
Raising livestock‡0.352
No973 (79.2)936 (96.2)37 (3.8)
Yes255 (20.8)242 (94.9)13 (5.1)
Grazing livestock0.165
Yes119 (9.7)117 (98.3)2 (1.7)
No1109 (90.3)1061 (95.7)48 (4.3)
Occupation0.437
Agriculture713 (58.1)680 (95.4)33 (4.6)
Stock farming31 (2.5)30 (96.8)1 (3.2)
Housewife85 (6.9)80 (94.1)5 (5.9)
Farm housewife160 (13.0)154 (96.3)6 (3.8)
Other239 (19.5)234 (97.9)5 (2.1)
Career duration, y0.006
1–20433 (35.3)423 (97.7)10 (2.3)
21–40256 (20.9)249 (97.3)7 (2.7)
>41539 (43.9)506 (93.9)33 (6.1)
Tick bite during lifetime0.171
Yes166 (13.5)156 (94.0)10 (6.0)
No1,062 (86.5)1,022 (96.2)40 (3.8)
Tick bite during previous year0.076
Yes75 (6.1)69 (92.0)6 (8.0)
No1,153 (93.9)1,109 (96.2)44 (3.8)
Awareness of SFTS0.446
Completely unaware500 (40.8)477 (95.4)23 (4.6)
Somewhat aware558 (45.5)535 (95.9)23 (4.1)
Completely aware169 (13.8)165 (97.6)4 (2.4)
History of SFTS or febrile illness during the fall0.575
Yes97 (7.9)92 (94.9)5 (5.2)
No1,130 (92.1)1,085 (96.0)45 (4.0)
Family history of SFTS or febrile illness during the fall0.235
Yes56 (4.6)52 (92.9)4 (7.1)
No1,171 (95.4)1,125 (96.1)46 (3.9)
SFTS-related symptoms during the previous 3 y0.002
Yes25 (2.0)21 (84.0)4 (16.0)
No1,202 (98.0)1,156 (96.2)46 (3.8)

*SFTS, severe fever with thrombocytopenia syndrome.
†By χ2 test.
‡Including cattle, goats, sheep, deer, and birds.

*SFTS, severe fever with thrombocytopenia syndrome.
†By χ2 test.
‡Including cattle, goats, sheep, deer, and birds. Among the total sample, 50 (4.1%) persons were seropositive for SFTSV (Figure 1): 23 (5.5%) in Boseong, 16 (4.0%) in Hapcheon, and 11 (2.7%) in Dangjin. Antibody seroprevalence was 2.3% (9/397) for persons <64 years of age and 4.9% (41/831) for persons >65 years of age (Table 1). Persons who had fever and GI symptoms in the previous 3 years were more likely to be seropositive. Antibody positivity was also higher for persons with a long career duration, but we did not identify any correlations with occupation type, outdoor activity–related characteristics, or type of work in the previous year. Furthermore, 50 persons had antibody titers >1:32, among whom 6 had had a tick bite in the previous year. Among these 6 persons, 5 (83.3%) had an antibody titer >1:128. For 44 persons who did not have tick bites in the previous year, 15 (34.1%) had an antibody titer >1:128. Persons who had a tick bite in the past year had significantly higher antibody titers (p = 0.021). We used multiple logistic regression analysis to identify variables with significant (p<0.1) probabilities of being associated with seropositivity. Persons who had fever and GI symptoms in the previous 3 years (odds ratio [OR] 4.09, 95% CI 1.25–13.36) and those who had a career duration of >41 years (OR 2.36, 95% CI 1.11–5.02) had a higher likelihood of seropositivity than nonsymptomatic persons and those who had a career duration of 1–20 years (Table 2). In addition, of 25 (2%) persons with fever and GI symptoms or suspected SFTS symptoms in the previous 3 years, 4 (16.0%) were SFTS seropositive; among the 1,202 with no suspected SFTS symptoms, 3.8% (n = 46) were SFTS seropositive (p = 0.002). Persons who had fever and GI symptoms in the previous 3 years were more likely to be seropositive for SFTSV.
Table 2

Risk factors associated with SFTSV seropositivity determined by using multiple logistic regression in rural areas, South Korea*

CharacteristicaOR (95% CI)
Age, y
<641.00
>651.45 (0.60–3.50)
No. family members
0 (alone) or 11.57 (0.64–3.87)
>21.00
Tick bite during previous year
No1.00
Yes1.60 (0.62–4.11)
SFTS-related symptoms during previous 3 y
No1.00
Yes4.09 (1.25–13.36)
Career duration
1–201.00
21–401.44 (0.52–3.99)
>412.36 (1.11–5.02)

*aOR, adjusted odd ratio; SFTSV, severe fever with thrombocytopenia syndrome virus.

*aOR, adjusted odd ratio; SFTSV, severe fever with thrombocytopenia syndrome virus.

Conclusions

A much higher mortality rate was observed for patients with SFTS in South Korea than for patients in China (). In addition, the high SFTS case-fatality rate in South Korea (47.2%, 17/36) is a serious public health concern (). The 3 areas examined in this study were rural, and most residents were elderly agriculture workers. In China, queried seropositive farmers denied having typical SFTS symptoms (). In contrast, despite possible recall bias in our study, seroprevalence was higher for patients who reported fever and GI symptoms (i.e., SFTS symptoms) during the previous 3 years. When 2,510 residents of Jiangsu Province, China, were subjected to SFTSV antibody testing, 1,104 (0.44%) were seropositive (). In contrast, a study of 2,547 farmers in a rural area of the same province reported a seropositivity rate of 1.3% (). Thus, SFTSV seroprevalence was 3-fold higher for rural farmers than for the general population (,). Li et al. also reported that seroprevalence tended to increase with age (). These findings might help to explain the relatively high seroprevalence (4.1%) observed in our study. Moreover, studies have indicated that mild or subclinical SFTS might be common. For example, SFTS viral antibody testing of healthy residents in Zhejiang Province, China, showed that 7.2% had IgG against SFTSV (). In this study, when persons were asked if they had had GI symptoms and fever in the previous 3 years, which indicated a suspected SFTSV infection, 25 (2.0%) persons, including 4 (8.0%) of 50 seropositive persons reported that they had had these suspected SFTS symptoms. Furthermore, persons who reported suspected SFTS symptoms were more likely to be seropositive. Therefore, subclinical or mild SFTSV infections might be present in the study communities. In addition, the higher antibody titers for persons who had ticks bites in the past year indicate a correlation between tick bites and antibody titer positivity. Long career duration was associated with SFTS seroprevalence in this study. Most study participants were elderly; age and career duration showed a weak positive correlation (r = 0.312, p<0.001). Additional research is needed to investigate SFTSV seroprevalence, including various age groups containing an adequate number of persons. Our study had some limitations. First, we did not use other seropositivity testing methods, such as ELISA, because of lack of availability. Second, recollection of symptoms (e.g., fever) on the questionnaire might have introduced recall bias. In summary, SFTSV seroprevalence was 4.1% for residents in 3 rural areas of South Korea. A history of fever and GI symptoms and a long career duration were associated with SFTSV seroprevalence.
  7 in total

1.  Severe fever with thrombocytopenia syndrome in China.

Authors:  Yi-Ting Xie; De-Hua Lai; Guang-Yuan Liu; Jin-Lin Zhou; Zhao-Rong Lun
Journal:  Lancet Infect Dis       Date:  2015-01-19       Impact factor: 25.071

2.  Epidemiologic features of severe fever with thrombocytopenia syndrome in China, 2011-2012.

Authors:  Fan Ding; Wenyi Zhang; Liya Wang; Wenbiao Hu; Ricardo J Soares Magalhaes; Hailong Sun; Hang Zhou; Sha Sha; Shenlong Li; Qiyong Liu; Qun Li; Weizhong Yang; Liuyu Huang; Chengyi Li; Wenwu Yin
Journal:  Clin Infect Dis       Date:  2013-02-19       Impact factor: 9.079

3.  Seroprevalence of antibodies against SFTS virus infection in farmers and animals, Jiangsu, China.

Authors:  Zhifeng Li; Jianli Hu; Changjun Bao; Pengfei Li; Xian Qi; Yuanfang Qin; Shenjiao Wang; Zhongmin Tan; Yefei Zhu; Fenyang Tang; Minghao Zhou
Journal:  J Clin Virol       Date:  2014-04-13       Impact factor: 3.168

4.  Seroprevalence and risk factors for severe fever with thrombocytopenia syndrome virus infection in Jiangsu Province, China, 2011.

Authors:  Shuyi Liang; Changjun Bao; Minghao Zhou; Jianli Hu; Fenyang Tang; Xiling Guo; Yongjun Jiao; Wenshuai Zhang; Peilin Luo; Luxun Li; Kuanyuan Zhu; Wenwen Tan; Qimei Lu; Hengming Ge; Abao Chen
Journal:  Am J Trop Med Hyg       Date:  2013-12-16       Impact factor: 2.345

5.  Severe fever with thrombocytopenia syndrome virus, South Korea, 2013.

Authors:  Sun-Whan Park; Myung-Guk Han; Seok-Min Yun; Chan Park; Won-Ja Lee; Jungsang Ryou
Journal:  Emerg Infect Dis       Date:  2014-11       Impact factor: 6.883

6.  Antibodies against severe fever with thrombocytopenia syndrome virus in healthy persons, China, 2013.

Authors:  Lei Zhang; Jimin Sun; Jie Yan; Huakun Lv; Chengliang Chai; Yi Sun; Bin Shao; Jianmin Jiang; Zhiping Chen; Jeroen Kortekaas; Yanjun Zhang
Journal:  Emerg Infect Dis       Date:  2014-08       Impact factor: 6.883

7.  Severe fever with thrombocytopenia syndrome virus in ticks collected from humans, South Korea, 2013.

Authors:  Seok-Min Yun; Wook-Gyo Lee; Jungsang Ryou; Sung-Chan Yang; Sun-Whan Park; Jong Yeol Roh; Ye-Ji Lee; Chan Park; Myung Guk Han
Journal:  Emerg Infect Dis       Date:  2014-08       Impact factor: 6.883

  7 in total
  8 in total

1.  Serologic Evidence of Severe Fever with Thrombocytopenia Syndrome Virus and Related Viruses in Pakistan.

Authors:  Ali Zohaib; Jingyuan Zhang; Muhammad Saqib; Muhammad Ammar Athar; Muhammad Hammad Hussain; Jing Chen; Awais-Ur-Rahman Sial; M Haleem Tayyab; Murrafa Batool; Saeed Khan; Yun Luo; Cecilia Waruhiu; Zeeshan Taj; Zulfiqar Hayder; Riaz Ahmed; Abu Bakr Siddique; Xinglou Yang; Muhammad Asif Qureshi; Ikram Uddin Ujjan; Amanullah Lail; Iahtasham Khan; Tao Zhang; Fei Deng; Zhengli Shi; Shu Shen
Journal:  Emerg Infect Dis       Date:  2020-07       Impact factor: 6.883

Review 2.  Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease.

Authors:  Joel N Maslow; Jackie J Kwon; Susan K Mikota; Susan Spruill; Youngran Cho; Moonsup Jeong
Journal:  Hum Vaccin Immunother       Date:  2019-07-16       Impact factor: 3.452

3.  A case of SFTS coinfected with E. coli bacteremia.

Authors:  Hyungdon Lee; Woo Young Choi; Choon Mee Kim; Na-Ra Yun; Dong-Min Kim; Sang-Hyun Pyun; Byung Jun Yu; You Mi Lee
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

4.  Effects of steroid therapy in patients with severe fever with Thrombocytopenia syndrome: A multicenter clinical cohort study.

Authors:  Sook In Jung; Ye Eun Kim; Na Ra Yun; Choon-Mee Kim; Dong-Min Kim; Mi Ah Han; Uh Jin Kim; Seong Eun Kim; Jieun Kim; Seong Yeol Ryu; Hyun Ah Kim; Jian Hur; Young Keun Kim; Hye Won Jeong; Jung Yeon Heo; Dong Sik Jung; Hyungdon Lee; Kyungmin Huh; Yee Gyung Kwak; Sujin Lee; Seungjin Lim; Sun Hee Lee; Sun Hee Park; Joon-Sup Yeom; Shin-Woo Kim; In-Gyu Bae; Juhyung Lee; Eu Suk Kim; Jun-Won Seo
Journal:  PLoS Negl Trop Dis       Date:  2021-02-19

5.  Accuracy of Real-Time Polymerase Chain Reaction in COVID-19 Patients.

Authors:  Merlin Jayalal Lawrence Panchali; Choon-Mee Kim; Hyeon Jeong Oh; You Mi Lee; Misbah Tariq; Jun-Won Seo; Da Young Kim; Na Ra Yun; Dong-Min Kim
Journal:  Microbiol Spectr       Date:  2022-02-16

6.  Clinical Score System to Differentiate Severe Fever with Thrombocytopenia Syndrome Patients from Patients with Scrub Typhus or Hemorrhagic Fever with Renal Syndrome in Korea.

Authors:  Dae Hyuk Heo; Yu Min Kang; Kyoung Ho Song; Jun Won Seo; Jeong Han Kim; June Young Chun; Kang Il Jun; Chang Kyung Kang; Song Mi Moon; Pyoeng Gyun Choe; Wan Beom Park; Ji Hwan Bang; Eu Suk Kim; Hong Bin Kim; Sang Won Park; Won Sup Oh; Nam Joong Kim; Myoung Don Oh
Journal:  J Korean Med Sci       Date:  2020-03-23       Impact factor: 2.153

7.  Seroprevalence of Severe Fever with Thrombocytopenia Syndrome in the Agricultural Population of Jeju Island, Korea, 2015-2017.

Authors:  Jeong Rae Yoo; Sang Taek Heo; Miyeon Kim; Sung Wook Song; Ji Whan Boo; Keun Hwa Lee
Journal:  Infect Chemother       Date:  2019-09-27

Review 8.  Clinical Update of Severe Fever with Thrombocytopenia Syndrome.

Authors:  Jun-Won Seo; Dayoung Kim; Nara Yun; Dong-Min Kim
Journal:  Viruses       Date:  2021-06-23       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.